Renal Metabolism of Glycolate to Oxalate
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 16, 2020
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the body processes a substance called glycolate and how this affects the amount of oxalate found in urine. Oxalate is a compound that can form kidney stones, so understanding its metabolism in healthy individuals is important. The researchers will use a special technique with a carbon isotope and have participants follow a low-oxalate diet to see how these factors influence oxalate levels in urine.
To be eligible for this trial, participants need to be healthy adults aged between 18 and 75 years, with a body mass index (BMI) between 19 and 40. They should be able to understand the study details and provide consent. Participants will need to collect their urine for 24 hours on two occasions for screening. It’s important to note that individuals with certain medical conditions, or those who are pregnant or breastfeeding, cannot participate. If you join this study, you will contribute to important research that might help improve our understanding of kidney health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mentally competent adults, able to read and comprehend the consent form
- • 18-75 years of age
- • Body Mass Index (BMI) between 19 and 40
- • In good health as judged from a medical history, reported medications, and a complete blood metabolic profile
- • Acceptable 24 hour urine collections (performed twice for screening)
- Exclusion Criteria:
- • History of any hepatic, renal, bowel, or endocrine disease or any other condition that may influence the absorption, transport or urine excretion of ions
- • Abnormal urine chemistries or blood metabolic profiles
- • Poor 24 hour urine collections completed during screening, judged by 24 hour urine creatinine excretion (indicative of not collecting all urine in the 24 hour period)
- • Pregnancy, intention to become pregnant in the near future, or lactation
- • Aged \<18 or \>75
- • BMI \<19 or \>40
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Sonia Fargue, M.D., Ph.D.
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials